Resverlogix Corp. Closes Additional $30 million from Citibank Loan

About this update from Resverlogix Corp.

[{"type":"text","content":"\n\n\nTSX Exchange Symbol: RVX\n\n\nCALGARY, Aug. 15, 2014 /CNW/ - Resverlogix Corp. (\"Resverlogix\")\n (TSX:RVX) announced today that it has closed the previously-announced\n amendments which provided for the loan granted to Resverlogix by\n Citibank, N.A. to be increased by $30 million to $68.8 million, as more\n particularly described in the management information circular dated\n July 14, 2014.\n\n\nAbout Resverlogix \n\n\nResverlogix Corp. (TSX: RVX) is a clinical stage cardiovascular company\n developing compounds involving a therapeutic increase in ApoA-I.\n Resverlogix's RVX-208 is a first-in-class small molecule for the\n treatment of atherosclerosis and other chronic diseases such as\n Diabetes Mellitus and Alzheimer's disease. RVX-208 is the first BET\n bromodomain inhibitor in clinical trials. Resverlogix's common shares\n trade on the Toronto Stock Exchange (TSX: RVX). For further information\n please visit www.resverlogix.com. We can be followed on our blog at http://www.resverlogix.com/blog.\n\n\nCompany Contacts:\n\n\nDonald J. McCaffrey\nPresident and CEO\nResverlogix Corp.\nPhone: 403-254-9252\nEmail: [email protected]\n\n\nSOURCE Resverlogix Corp.\n\n\n\nCopyright CNW Group 2014","length":1997,"tagName":"div"}]

More updates from Resverlogix Corp.